Parkinson's disease (PD) is a chronic neurodegenerative disorder accompanied with several cardinal motor characteristic symptoms including resting tremor, postural instability, rigidity and bradykinesia. Previous studies have proved that PD was a result of the depletion of dopaminergic neurons in substantianigra[@b1]. In addition, age *per se* is a key factor that affects PD's pathogenesis and progression by changing cellular processes and functions that related with neurodegeneration[@b2].

PD is one of the most common neurodegenerative diseases ranking only second to Alzheimer's disease[@b3]. According to a rough estimation performed by Twelves *et al*., incidence of PD around the world was around 16--19 per 100,000 people per year, with highest incidence in males aging between 70 and 79 years[@b4]. Since population worldwide is aging gradually, it is predicted by Dorsey *et al*. that the population of patients affected by PD will double in 2030[@b5]. Apart from the high prevalence rate among elder males, PD is also characterized with a high mortality. In a 20 years follow-up of 136 patients diagnosed with new-onset PD, a high mortality of 74% was observed and dementia occurred in 83% of the remaining survivors[@b6].

So far, all treatments for PD were aimed at alleviating its clinical symptoms and improving the life quality of patients and no curative therapy has been developed to reverse the underlying neurodegenerative process[@b7]. Levodopa, dopamine agonists (DA) and monoamine oxidase type B inhibitors (MAOBI) are mainstream drugs that are widely used as first-line treatments of PD. Among them, levodopa performed best in symptomatic control and it guaranteed at least 50% improvement in symptomatic for a period of 2 to 3 years[@b8]. However, levodopa would cause increased dyskinesia, motor fluctuations and other adverse effects in the long term[@b9][@b10]. To prolong the beneficial effect of motor symptomatic control, levodopa is often combined with DA or MAOBI as adjunctive therapy for all-stage PD patients. DA, such as bromocriptine, cabergoline, pergolide, pramipexole, ropinirole and rotigotine, is a class of drugs that act on D2 receptors and work well in controlling motor fluctuations[@b7]. Apart from acting as an adjunct therapy to levodopa, it's also widely used as monotherapy for PD in early stages to delay the utilization of levodopa therapy[@b11]. Monoamine oxidase type B (MAOB) is the leading enzyme regulating concentrations of neurotransmitters such as acetylcholine and dopamine that are related with emotion, movement and cognition in human brain[@b12]. In clinical trials, its inhibitor has been used to down-regulate the degree of on-off motor fluctuations[@b13]. Rasagiline and selegiline are both selective and irreversible MAOBI and now used as anti-Parkinson drug or adjunct to levodopa, wherein former one is more potent *in vivo*[@b13][@b14]. Besides, lazabemide is also a drug of MAOBI. Similarly, their adverse motor effects such as dizziness, wearing-off, on-off phenomena and insomnia also raised concerns.

Tough numerous placebo-controlled trails have been implemented to assess efficacy of anti-Parkinson drugs, no comprehensive comparisons for efficacy and tolerability among all available treatments were conducted. As such, present study was designed to make comparisons of monotherapy's efficacy and tolerability among ten drugs mentioned above by combining evidence from previous randomized controlled trials (RCTs).

Results
=======

Study characteristics
---------------------

As presented in [Figure S1](#S1){ref-type="supplementary-material"}, 110 publications involving 24,864 participants were finally included in the present study after screening 1,154 publications according to the inclusion criteria[@b13][@b15][@b16][@b17][@b18][@b19][@b20][@b21][@b22][@b23][@b24][@b25][@b26][@b27][@b28][@b29][@b30][@b31][@b32][@b33][@b34][@b35][@b36][@b37][@b38][@b39][@b40][@b41][@b42][@b43][@b44][@b45][@b46][@b47][@b48][@b49][@b50][@b51][@b52][@b53][@b54][@b55][@b56][@b57][@b58][@b59][@b60][@b61][@b62][@b63][@b64][@b65][@b66][@b67][@b68][@b69][@b70][@b71][@b72][@b73][@b74][@b75][@b76][@b77][@b78][@b79][@b80][@b81][@b82][@b83][@b84][@b85][@b86][@b87][@b88][@b89][@b90][@b91][@b92][@b93][@b94][@b95][@b96][@b97][@b98][@b99][@b100][@b101][@b102][@b103][@b104][@b105][@b106][@b107][@b108][@b109][@b110][@b111][@b112][@b113][@b114][@b115][@b116][@b117][@b118][@b119][@b120][@b121][@b122][@b123]. Baseline characteristics were shown in [Table 1](#t1){ref-type="table"}. As we can see, all these studies were designed as RCTs and most of them were double-blind RCTs. Patients were diagnosed as either early or advanced PD and most of them were male above 60. Besides, we draw a network of included trials in [Fig. 1](#f1){ref-type="fig"}, from which we observed that most RCTs had taken placebo as the control group. Among all interventions, Pramipexole, Ropinirole, Levodopa and Rasagiline were involved in most studies and had relative bigger sample sizes.

Meta-analysis results for pair-wise comparisons
-----------------------------------------------

Meta-analysis results for pair-wise comparisons were shown in [Table 2](#t2){ref-type="table"}. We found that lazabemide exhibited a worse efficacy with respect to UPDRS II compared with placebo (MD = 0.82, CI: 0.29 to 1.34). Patients with levodopa, pramipexole, ropinirole, rotigotine and selegiline all functioned better with respect to UPDRS II and III than those with placebo. With respect to UPDRS total, lazabemide also functioned worse than placebo (MD = 1.88, CI: 0.57 to 3.19) while bromocriptine, levodopa, rasagiline and selegiline functioned better. Besides, selegiline had a higher score in UPDRS II, UPDRS III and UPDRS total than bromocriptine and levodopa. As for withdrawal, only rotigotine had a significant lower withdrawal rate than placebo. Besides, selegiline was more tolerable than bromocriptine (OR = 0.62, CI: 0.39 to 0.98) and pramipexole had a higher withdraw rate than levodopa (OR = 1.43, CI = 1.00 to 2.04).

Network meta-analysis results
-----------------------------

As we can see in [Table 3](#t3){ref-type="table"} and [Figures S2--5](#S1){ref-type="supplementary-material"}, for UPDRS II, levodopa, pramipexole, ropinirole, rotigotine and selegiline exhibited increased efficacy compared to placebo and lazabemide All interventions except for cabergoline, lazabemide, pergolide and rasagiline exhibited an increased efficacy compared to the placebo with respect to UPDRS III. Patients with levodopa, pramipexole, ropinirole and selegiline exhibited a significantly improved UPDRS III than those with lazabemide. Our NMA suggests that only patients with selegiline exhibited significantly improved UPDRS total than those with placebo (MD = −6.04, CrI: −11.07 to −0.83). On the other hand, patients with levodopa or ropinirole exhibited a lower risk of withdrawals compared to those with placebo and bromocriptine (ORs \< 1). Finally, selegiline appeared to have higher withdraw rate than levodopa, ropinirole and rotigotine with respect to the likelihood of withdrawals (OR = 2.43, CrI: 1.42 to 4.23; OR = 2.17, CrI: 1.27 to 3.84; OR = 1.93, CrI: 1.08 to 3.51).

Cumulative ranking probability as a ranking scheme
--------------------------------------------------

[Table 4](#t4){ref-type="table"} and [Figure S6](#S1){ref-type="supplementary-material"} showed the cumulative ranking probability of all interventions based on each outcome. Three drugs including ropinirole, pramipexole, and selegiline ranked first in UPDRS II, III and total (with the value of 0.773, 0.777 and 0.918 respectively, and levodopa had the highest rank in withdraw rate. Besides, selegiline ranked the first in UPDRS total but the last in withdrawal. Levodopa and ropinirole had a high ranking when taking withdrawals into consideration. Besides, lazabemide was a mild intervention with both low efficacy rank and withdrawal rate. Cluster analysis presented results above in a more intuitional way ([Fig. 2](#f2){ref-type="fig"}). Interventions with the same level of SUCRA values are displayed in the same color. Levodopa, ropinirole and rotigotine fall into the group with both the most favorable SUCRA values and tolerability as well.

Consistency
-----------

In node-splitting plot ([Figure S7](#S1){ref-type="supplementary-material"}), all *P*-values are higher than 0.05, which indicated a relatively satisfactory consistency between direct and indirect evidence. In heat map ([Fig. 3](#f3){ref-type="fig"}), consistency between direct evidence and NMA results in UPDRS II and withdrawal was well-pleasing. However, there appeared to be some significant inconsistency between direct and indirect evidence in UPDRS III and UPDRS total.

Discussion
==========

This study made a comprehensive comparison for the tolerability and efficacy among anti-Parkinson drugs by using a network meta-analysis. Interventions were grouped into placebo, DA (Pramipexole, Ropinirole and Rotigotine), MAOBI (- Rasagiline and Selegiline) and Levodopa. Efficacy outcomes included unified PD rating scale (UPDRS) II, UPDRS III and UPDRS total. Taking tolerability, efficacy and adverse effect into consideration, we also examined withdraw rate, treatments with high withdraw rate means lacking of efficacy, safety or easy to become tolerant. To our knowledge, this is the first study that well explored the efficacy and tolerability ranking of these three types of drugs for Parkinson with a great range of outcomes included.

Levodopa is an intervention that is widely used in clinical trials with good control of symptoms of PD. Noticeably, levodopa is one of the best tolerated treatments for PD, particularly in the elderly patients[@b124]. Our research indicated the same result that levodopa ranked high in UPDRS II and III, and maintained a very low withdraw rate, which possessed a very favorable balance between efficacy and tolerability and worthy of recommendation. However, it may still cause several long-term adverse events including motor complications and dyskinesia[@b125].

The efficiency of DA in reducing motor fluctuations and dyskinesias has been reported by previous studies[@b126][@b127]. For instance, Rascol *et al*. found that patients with early PD can be well controlled with a low risk of dyskinesia by an initial therapy of ropinirole, an agent of DA, alone. Also, a levodopa-controlled trial conducted by FulvioBracco *et al*. suggested that patients with PD were in a lower risk of motor fluctuations when treated with cabergoline, another agent of DA, though the relative safety was at the expense of a mildly improved clinical symptom[@b24]. Thus, these drugs were usually added into levodopa to weaken its adverse effects in clinical trials.

Compared to levodopa, MAOBI was found to decrease the incidence of disability during the treatment and motor fluctuations without any notable mortality rate or adverse effects[@b128]. Whereas, this meta-analysis conducted by Ives N.J. *et al*. was short of direct comparisons between MAOBIs and other types of anti-Parkinson drugs and thus was not sufficient.

Though our results were consistent with most previous trials, there still exist several flaws. One of the limitations in this study is that we only research on the monotherapy for PD. However, in clinical trials, it's common that these drugs were applied together to offset the corresponding adverse effects or the low efficacy rate raised by monotherapy. Besides, some other influence factors such as dosages, design and sample size may affect the accuracy and reliability of our results. For this, more clinical trials in comparisons of these interventions are in desperate need.

In our results, according to SUCRA, four drugs including levodopa, pramipexole, ropinirole and selegiline all had a well performance in UPDRS II and UPDRS III. And among them, selegiline had a highest UPDRS total and highest withdraw rate. Levodopa and ropinirole had a higher ranking when withdrawals were taken into consideration. Although lazabemide was a mild intervention with low efficacy rank and withdrawal rate, it has not been introduced in the market and not available for the patients. Besides, in cluster analysis, levodopa, ropinirole and rotigotine steadily ranked first in view of three endpoints including UPDRS II, UPDRS III and withdrawal. The network meta-analysis integrated evidence from 110 independent RCTs and thus provided an accurate results and smaller random errors.

In conclusion, levodopa, selegiline, ropinirole and rotigotine were recommended for PD patients for their relatively high efficacy and tolerability. If necessary, an appropriate composition of these drugs will perform well with a relative low risk of adverse effects and a high efficacy.

Methods and Materials
=====================

Search strategy
---------------

Publications in PubMed, Embase and Cochrane Library were retrieved without language restrictions. Keywords included Parkinson disease, bromocriptine, cabergoline, lazabemide, levodopa, pergolide, pramipexole, rasagiline, ropinirole, rotigotine, selegiline and RCTs. Publications were first screened by reviewing their titles and abstracts and further reviewed by scanning full texts. In addition, cited references attached to the included documents were also retrieved.

Inclusion criteria
------------------

Studies were included when they met the following criteria:Experiments were designed as RCTs comparing the efficacy of treatments for PD.Patients or participants were adults diagnosed with PD.Outcomes in studies included at least one of the following endpoints: Unified Parkinson's Disease Rating Scale (UPDRS) II, UPDRS III, UPDRS total and withdrawals.Interventions included at least one of the following drugs: bromocriptine, cabergoline, lazabemide, levodopa, pergolide, pramipexole, rasagiline, ropinirole, rotigotine and selegiline.

Data extraction
---------------

After reading through the full text, the following information was extracted from each independent study: author, publication year, sample size, gender ratio, design, blind, follow-up, age, condition of PD, intervention and dosage. As for outcomes, several unified PD rating scales (UPDRS) including UPDRS II, UPDRS III and UPDRS total were extracted if available, which has been considered as the primary efficacy outcomes in this analysis; meanwhile the rate of withdraw during the treatment was adopted as an endpoint integrating tolerability, efficacy and adverse effect as a whole.

Statistical analysis
--------------------

STATA version 12.0 (Stata Corp, College Station, TX, USA) software was applied in traditional meta-analysis. Firstly, the heterogeneity was examined by using Cochran's *Q*-statistic or *I*^*2*^ test. When significant heterogeneity did not exist (*P* \> 0.05 or *I*^*2*^\<50%), a fixed-effects model (*Mantel-Haenszel* method) was performed. Otherwise, we tried to find out the source of heterogeneity and eliminate the potential source of heterogeneity. Alternatively, a random-effects model (*Der Simonian-Laird* method) would be applied. For count data such as withdrawal, odd ratios (OR) and corresponding 95% confidence interval (CI) were calculated. For measurement data including UPDRS II, UPDRS III, UPDRS total, withdrawals, the mean difference (MD) and the corresponding 95% CI were calculated.

WinBUGS (MRC Bio-statistics Unit, Cambridge, UK) software was applied in network meta-analysis (NMA). To combine both direct and indirect evidence, a *Markov chain Monte Carlo* method and Bayesian networks were built. Similar with cases in traditional meta-analysis, OR and MD were separately used in count data and measurement data. Meanwhile, the corresponding 95% credential interval (CrI) was also calculated. To illustrate the results from NMA more directly, the surface under the cumulative ranking curve (SUCRA) was drawn and presented the ranking according to different endpoints. SUCRA enable us to identify the best treatment overall. The value of SUCRA would be 1 (i.e. 100%) for the best and 0 for the worst. In addition, a cluster analysis was conducted to combine the ranking under two independent endpoints and divide the interventions into several levels in view of their performan

Consistency between direct and indirect evidence was assessed by *P*-value and *P* \> 0.05 exhibited a significant consistency. A heat map was plotted to present the consistency between direct evidence and NMA results, in which red indicates significant inconsistency while blue indicates significant consistency.
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![The network plot of included trials.\
Each node represents a therapy of PD, the number beside the nodes represents the number of people involved and the number between two nodes represents the number of study involved in the head-to-head comparison.](srep45865-f1){#f1}

![Clustered ranking plot of the network.\
The plot is based on cluster analysis of surface under the cumulative ranking curves (SUCRA) values. Each plot shows SUCRA values for two outcomes. Each color represents a group of treatments that belong to the same cluster. Treatments lying in the upper right corner are more effective and safe than the other treatments.](srep45865-f2){#f2}

![Net heat plot.\
The size of the gray squares indicates the contribution of the direct evidence (shown in the column) to the network evidence (shown in the row). The colors are associated with the change in inconsistency between direct and indirect evidence (shown in the row). Blue colors indicate an increase of inconsistency and warm colors indicate a decrease.](srep45865-f3){#f3}

###### Characteristics of studies included in the network meta-analysis.

  Study                         Size   Male    Blind[\*](#t1-fn1){ref-type="fn"}   Follow-up (months)   Age\>   Early/Advanced PD                       Intervention                       Dosage
  ---------------------------- ------ ------- ----------------------------------- -------------------- ------- ------------------- ------------------------------------------------------- -----------------------------------
  Adler 1997                    241    62.2%                   2                           6            62.8          Early                        Ropinirole vs. Placebo                  15.7 mg/d
  Ahlskog 1988                   49    71.4%                   2                           6            50.0        Advanced                        Pergolide vs. Placebo                  0.75 mg/d
  Ahlskog 1996                   27    74.1%                   2                           6            63.9     Early/Advanced                    Cabergoline vs. Placebo                 5 mg/d
  Allain 1993                    93    53.8%                   2                           3            65.0          Early                        Selegiline vs. Placebo                  10 mg/d
  Antonini 2015                 349    56.2%                   2                          4.8           67.5     Early/Advanced                    Rotigotine vs. Placebo                  12 mg/d
  Barone 2007                   624    62.0%                   2                           10           64.6        Advanced                       Ropinirole vs. Placebo                  18 mg/d
  Barone 2010                   296    47.3%                   2                           3            67.0          Early                        Pramipexole vs. Placebo                 2.18 mg/d
  Barone 2015                   123    52.8%                   2                           3            66.0          Early                        Rasagiline vs. Placebo                  1 mg/d
  Blindeauer 2003               242    63.6%                   2                          2.8           61.3          Early                        Rotigotine vs. Placebo                  4.5, 9, 13.5, 18 mg
  Bracco 2004                   419    51.0%                   2                           60           61.4          Early                       Cabergoline vs. Levodopa                 2.85 mg/d vs 784 mg/d
  Brooks 1998                    63    51.0%                   2                           3            58.3     Early/Advanced                    Ropinirole vs. Placebo                  6.54 mg/d
  Brunt 2002                    206    59.6%                   2                           6            65.8        Advanced                    Ropinirole vs. Bromocriptine               9, 10, 14 mg/d vs 18, 19, 24 mg/d
  Caraceni 2001                 473    52.0%                   0                           34           63.3     Early/Advanced           Levodopa vs. Bromocriptine vs. Selegiline        750 mg/d vs 60 mgd vs 10 mg/d
  Giladi 2007                   561    57.7%                   2                          9.3           61.2          Early                 Rotigotine vs. Ropinirole vs. Placebo          8 mg/d vs 14.1 mg/d
  Golbe 1988                     96     ---                    2                          1.5           62.4        Advanced                       Selegiline vs. Placebo                  10 mg/d
  Grosset 2005                  106    67.0%                   2                          17.3          61.0          Early                         Pergolide vs. Placebo                  0.05 mg/d
  Guttman 1997                  246    63.4%                   2                           9            62.7        Advanced              Pramipexole vs. Bromocriptine vs. Placebo        3.36 mg/d vs 22.64 mg/d
  Hanagasi 2011                  48    68.8%                   2                           3            66.4          Early                        Rasagiline vs. Placebo                  1 mg/d
  Hauser 2007                    69    58.0%                   2                          120           62.1          Early                        Ropinirole vs. Levodopa                 14.5 mg/d vs 800.2 mg/d
  Hauser 2010                   259    55.6%                   2                          4.5           62.1          Early                        Pramipexole vs. Placebo                 1.37, 1.39 mg/d
  Hauser 2014                   326    68.0%                   2                          4.5           62.6          Early                        Rasagiline vs. Placebo                  1 mg/d
  Hauser 2015                   778    56.0%                   2                           3            63.3        Advanced                       Rasagiline vs. Placebo                  1 mg/d
  Hely 1994                     126    55.6%                   2                           60           62.0          Early                      Bromocriptine vs. Levodopa                31 mg/d vs 427 mg/d
  Holloway 2000                 301    64.8%                   2                          23.5          61.2          Early                       Pramipexole vs. Levodopa                 1.5 mg/d vs 300 mg/d
  Holloway 2004                 183    64.5%                   2                           48           60.9          Early                       Pramipexole vs. Levodopa                 1.5 mg/d vs 300 mg/d
  Holloway 2009                 301    61.7%                   0                           72           60.2          Early                       Pramipexole vs. Levodopa                 3 mg/d vs 450 mg/d
  Hubble 1995                    55    63.6%                   2                          2.25          63.3          Early                        Pramipexole vs. Placebo                 0.3--4.5 mg/d
  Hutton 1996                   188    66.5%                   2                           6            63.4     Early/Advanced                    Cabergoline vs. Placebo                 0.5--5 mg/d
  Im 2003                        76    54.0%                   0                           4            61.7     Early/Advanced                 Ropinirole vs. Bromocriptine               7.9 mg/d vs 15.4 mg/d
  Inzelberg 1996                 44    63.6%                   2                           9            71.0     Early/Advanced                 Cabergoline vs. Bromocriptine              3.18 mg/d vs 22.05 mg/d
  Jankovic 2014                 883     ---                    2                           9            62.8          Early                        Rasagiline vs. Placebo                  1 mg/d
  Jansen 1978                    23    56.5%                   2                           5            59.0        Advanced                      Bromocriptine vs. Placebo                71 mg/d
  Kieburtz 1993                 201    67.7%                   2                           1            63.0          Early                        Lazabemide vs. Placebo                  100, 200, 400 mg/d
  Kieburtz 1996                 321    71.2%                   2                           13           64.1          Early                        Lazabemide vs. Placebo                  23, 50, 100, 200 mg/d
  Kieburtz 1997                 264    64.4%                   2                          2.5           61.7          Early                        Pramipexole vs. Placebo                 1.5, 3, 4.5, 6 mg/d
  Kieburtz 2011                 311    66.6%                   2                           3            62.8          Early                        Pramipexole vs. Placebo                 0.50 mg tid, 0.50, 0.75 mg bid
  Kim 2015                       48    50.0%                   2                          0.2           24.0         Healthy                       Rotigotine vs. Placebo                  2&4 mg/d
  Koller 1993                   376     ---                    2                           3             ---          Early                        Selegiline vs. Placebo                  10 mg/d
  Kulisevsky 1998                20    35.0%                   0                           6            65.7     Early/Advanced                    Pergolide vs. Levodopa                  2.8 mg/d vs 435 mg/d
  Kulisevsky 2000                20    35.0%                   0                           6            65.7          Early                        Pergolide vs. Levodopa                  2.8 mg/d vs 435 mg/d
  Larsen 1999                   163     ---                    2                           60           55.0          Early                        Selegiline vs. Placebo                  10 mg/d
  LeWitt 2007                   349    63.9%                   2                          7.5           65.0        Advanced                       Rotigotine vs. Placebo                  7.16, 9.51 mg/d
  Lieberman 1997                360    65.0%                   2                           8            63.3        Advanced                       Pramipexole vs. Placebo                 2.44 mg/d
  Lieberman 1998                149     ---                    2                           6             ---     Early/Advanced                    Ropinirole vs. Placebo                  15.75 mg/d
  Lim 2015                       30    53.3%                   2                           3            67.2        Advanced                       Rasagiline vs. Placebo                  1 mg/d
  Mally 1995                     20    65.0%                   2                          1.5           62.5     Early/Advanced                    Selegiline vs. Placebo                  10 mg/d
  Marek 2002                     82    62.6%                   2                           46           61.0          Early                       Pramipexole vs. Levodopa                 1.5 mg/d vs 300 mg/d
  Maier Hoehn 1985               36    75.0%                   2                           10           62.9     Early/Advanced                   Bromocriptine vs. Placebo                1.25--20 mg/d
  Mendzelevski 2014             247    46.8%                   2                          0.3           21.0         Healthy                       Rasagiline vs. Placebo                  1, 2, 6 mg/d
  Mizuno 2003                   315    52.7%                   2                           3            64.6        Advanced              Pramipexole vs. Bromocriptine vs. Placebo        3.24 mg/d vs 17.75 mg/d
  Mizuno 2007                   241    44.4%                   2                           4            65.0        Advanced                       Ropinirole vs. Placebo                  7.12 mg/d
  Mizuno 2013                   176    39.8%                   2                          3.8           66.0          Early                        Rotigotine vs. Placebo                  12.8 mg/d
  Mizuno 2014                   420    41.3%                   2                           5            65.0        Advanced                Rotigotine vs. Ropinirole vs. Placebo          12.9 mg/d vs 9.2 mg/d
  Moller 2005                   354    65.0%                   2                          7.8           64.0        Advanced                       Pramipexole vs. Placebo                 3.7 mg/d
  Myllyla 1995                   44    47.7%                   2                           24           60.7     Early/Advanced                    Selegiline vs. Placebo                  10 mg/d
  Myllyla 1997                   44    48.8%                   2                           60           60.7     Early/Advanced                    Selegiline vs. Placebo                  10 mg/d
  Navan 2003                     10    60.0%                   2                          4 h           65.3          Early                 Pramipexole vs. Pergolide vs. Placebo          0.5 mg vs 0.5 mg
  Navan 2003                     30    63.3%                   2                           3            69.0     Early/Advanced             Pramipexole vs. Pergolide vs. Placebo          4.5 mg/d vs 4.5 mg/d
  Nicholas 2014                 514    69.8%                   2                           4            64.5        Advanced                       Rotigotine vs. Placebo                  2, 4, 6, 8 mg/d
  Nomoto 2014                   174    44.8%                   2                          4.8           67.0        Advanced                       Rotigotine vs. Placebo                  16 mg/d
  Oertel 2006                   294    56.8%                   2                           36           58.9          Early                        Pergolide vs. Levodopa                  3.23 mg/d vs 504 mg/d
  Olanow 1994                   376    63.6%                   2                           6            63.0        Advanced                        Pergolide vs. Placebo                  2.94 mg/d
  Olanow 1995                   101    68.3%                   2                           14           66.2          Early         Selegiline vs. Levodopa vs. Bromocriptine vs. Placebo  10 mg/d vs 400 mg/d vs 28 mg/d
  Olanow 2009                   1176   61.1%                   2                           9            62.2     Early/Advanced                    Rasagiline vs. Placebo                  1, 2 mg/d
  Pahwa 2007                    393    62.9%                   2                           6            66.2        Advanced                       Ropinirole vs. Placebo                  18.8 mg/d
  Pahwa 2014                    381    55.6%                   2                          7.5           65.0          Early                         Levodopa vs. Placebo                   145, 245, 390 mg tid
  Palhagen 1998                 157    59.3%                   2                           6            63.7          Early                        Selegiline vs. Placebo                  10 mg/d
  Parkinson Study Group 1994    137    66.4%                   2                           1            67.0          Early                        Lazabemide vs. Placebo                  100, 200, 400 mg/d
  Pinter 1999                    78    65.4%                   2                          2.8           60.1        Advanced                       Pramipexole vs. Placebo                 3.59 mg/d
  Poewe 2007                    506    62.9%                   2                          6.8           64.0        Advanced               Pramipexole vs. Rotigotine vs. Placebo          3.1 mg/d vs 12.95 mg/d
  Poewe 2011                    539    55.5%                   2                          8.3           62.0          Early                        Pramipexole vs. Placebo                 2.9 mg/d
  Poewe 2015                    174    57.5%                   2                           12           65.0          Early                        Rasagiline vs. Placebo                  1 mg/d
  Pogarell 2002                  84    72.3%                   2                           3            63.6     Early/Advanced                    Pramipexole vs. Placebo                 4.1 mg/d
  Presthus 1983                  38    52.6%                   2                           1            65.8     Early/Advanced                    Selegiline vs. Placebo                  5 mg/d
  Rabey 2000                     70    55.7%                   2                           3            57.0     Early/Advanced                    Rasagiline vs. Placebo                  0.5, 1, 2 mg/d
  Rascol 1996                    46    60.9%                   2                           3            62.5     Early/Advanced                    Ropinirole vs. Placebo                  3.3 mg/d
  Rascol 1998                   268    61.2%                   2                           6            63.0          Early                        Ropinirole vs. Levodopa                 9.7 mg/d vs 464.0 mg/d
  Rascol 2000                   268    61.6%                   2                           60           63.0          Early                        Ropinirole vs. Levodopa                 16.5 mg/d vs 753 mg/d
  Rascol 2005                   460    62.2%                   2                          4.5           64.3     Early/Advanced                    Rasagiline vs. Placebo                  1 mg/d
  Rascol 2015                    68    52.9%                   2                           3            65.9        Advanced                       Rotigotine vs. Placebo                  14.7 mg/d
  Rektorova 2003                 41    61.0%                   2                           8            61.5        Advanced                      Pramipexole vs. Pergolide                2.7 mg/d vs 3.0 mg/d
  Rinne 1998                    412    48.5%                   2                           6            61.5          Early                       Cabergoline vs. Levodopa                 3 mg/d vs 500 mg/d
  Sampaio 2011                  225    58.2%                   2                           6            61.8          Early                        Pramipexole vs. Placebo                 2.25 mg/d
  Schapira 2011                 507    54.9%                   2                          4.5           61.5        Advanced                       Pramipexole vs. Placebo                 2.7, 2.8 mg/d
  Schiwid 2005                  472    64.6%                   2                          6.5           63.3          Early                        Rasagiline vs. Placebo                  0.5, 1.0 mg/d
  Sethi 1998                    147    62.6%                   2                           12           62.0          Early                        Ropinirole vs. Placebo                  17.9 mg/d
  Shannon 1997                  335    60.6%                   2                           6            62.7          Early                        Pramipexole vs. Placebo                 3.8 mg/d
  Siderowf 2002                 404    63.6%                   2                          6.5           60.8          Early                        Rasagiline vs. Placebo                  1, 2 mg/d
  Singer 2007                   405    62.0%                   2                           10           65.0          Early                        Ropinirole vs. Placebo                  12.4 mg/d
  Smith 2015                    191     ---                    2                           9            61.2          Early                        Rasagiline vs. Placebo                  1--2 mg/d
  Steiger 1996                   37     ---                    2                           3            62.1     Early/Advanced                    Cabergoline vs. Placebo                 5.4 mg/d
  Stern 2004                     56    67.9%                   2                          2.5           61.5          Early                        Rasagiline vs. Placebo                  1, 2, 4 mg/d
  Stocchi 2008                  161    54.0%                   2                           5            60.3          Early                       Ropinirole vs. Ropinirole                8.9 mg/d vs 18.6 mg/d
  Stocchi 2011                   69    69.6%                   2                          4.5           64.2     Early/Advanced                    Rasagiline vs. Placebo                  1 mg/d
  Storch 2013                    35    68.6%                   1                           3            61.7          Early                       Cabergoline vs. Levodopa                 3 mg/d vs 300 mg/d
  Tanner 2007                   144    65.0%                   2                          2.5           65.0        Advanced                       Pramipexole vs. Placebo                 4.5 mg/d
  Tetrud 1989                    54    68.5%                   2                           36           61.0          Early                        Selegiline vs. Placebo                  10 mg/d
  Thomas 2006                    52    55.8%                   2                           24           56.2          Early                      Ropinirole vs. Pramipexole                15 mg/d vs 521 mg/d
  Timmermann 2015               346    61.7%                   2                           6            67.0          Early                        Rotigotine vs. Placebo                  8.5 m/d
  Toyokur 1985                  222    49.1%                   2                           2            63.0     Early/Advanced                   Bromocriptine vs. Placebo                2.5 mg/d
  Trenkwalder 2011              287    64.1%                   2                           2            64.7     Early/Advanced                    Rotigotine vs. Placebo                  16 mg/d
  Utsumi 2012                    91    47.3%                   0                           60           62.0          Early                       Cabergoline vs. Levodopa                 2.9 mg/d vs 325 mg/d
  Viallet 2013                  109    62.4%                   2                          3.8           62.6          Early                      Rasagiline vs. Pramipexole                1 mg/d vs 1.5 mg/d
  Waters 2004                   140    63.6%                   2                           3            65.3     Early/Advanced                    Selegiline vs. Placebo                  1.875 mg/d
  Weintraub 2016                170    78.0%                   2                           6            67.5          Early                        Rasagiline vs. Placebo                  1 mg/d
  Wermuth 1998                   69    58.0%                   2                          2.8           62.1        Advanced                       Pramipexole vs. Placebo                 5 mg/d
  Whone 2003                    162    67.3%                   2                           24           60.5          Early                        Ropinirole vs. Levodopa                 12.2 mg/d vs 558.7 mg/d
  Wong 2003                     150    69.3%                   2                          3.8           60.0     Early/Advanced                    Pramipexole vs. Placebo                 2.44 mg/d
  Zhang 2013                    219    59.8%                   2                           3            61.6     Early/Advanced                    Rasagiline vs. Placebo                  1 mg/d
  Zhang 2014                    345    64.1%                   2                           6            63.9        Advanced                       Ropinirole vs. Placebo                  11.4 mg/d

^\*^Blind: 0, open label; 1, single blind; 2, double blind. Abbreviation: PD, Parkinson's disease

###### Meta-analysis results for pair-wise comparisons according to UPDRS II, UPDRS III, UPDRS total represented by mean difference (MD) and 95% confidence interval (CI) and withdrawals represented by odds ratio (OR) with 95% confidence interval (CI).

  Treatment 1       Treatment 2            UPDRS II                   UPDRS III                  UPDRS total               Withdrawals
  --------------- --------------- -------------------------- --------------------------- --------------------------- -----------------------
  Bromocriptine       Placebo      **−1.02 (−1.31, −0.73)**      −2.27 (−6.11, 1.56)      **−1.30 (−1.87, −0.73)**      1.03 (0.57, 1.85)
  Cabergoline         Placebo      **−2.30 (−4.40, −0.20)**      −1.60 (−4.07, 0.87)                 ---                0.65 (0.31, 1.41)
  Lazabemide          Placebo       **0.82 (0.29, 1.34)**        0.83 (−0.18, 1.83)         **1.88 (0.57, 3.19)**       0.68 (0.34, 1.36)
  Levodopa            Placebo      **−2.26 (−4.49, −0.03)**   **−6.05 (−12.06, −0.04)**   **−4.10 (−4.75, −3.45)**      0.98 (0.58, 1.63)
  Pergolide           Placebo                ---                         ---                         ---                1.02 (0.66, 1.58)
  Pramipexole         Placebo      **−1.48 (−2.02, −0.94)**   **−3.86 (−5.87, −1.86)**       1.25 (−7.66, 10.15)        0.96 (0.73, 1.27)
  Rasagiline          Placebo        −0.17 (−1.94, 1.60)         −1.86 (−4.30, 0.58)      **−2.30 (−4.00, −0.60)**      0.94 (0.76, 1.15)
  Ropinirole          Placebo      **−1.90 (−2.28, −1.52)**   **−5.05 (−5.95, −4.15)**               ---                0.76 (0.56, 1.05)
  Rotigotine          Placebo      **−1.43 (−2.50, −0.36)**   **−3.12 (−5.48, −0.76)**               ---              **0.78 (0.62, 0.98)**
  Selegiline          Placebo      **−1.46 (−2.48, −0.43)**   **−3.85 (−5.89, −1.81)**    **−6.46 (−10.50, −2.43)**     1.39 (0.94, 2.04)
  Cabergoline      Bromocriptine      0.00 (−3.04, 3.04)         2.00 (−5.68, 9.68)                  ---                0.71 (0.20, 2.60)
  Levodopa         Bromocriptine     −0.20 (−0.53, 0.13)      **−2.60 (−2.95, −2.25)**    **−2.80 (−3.41, −2.19)**      0.37 (0.09, 1.50)
  Pramipexole      Bromocriptine     −0.73 (−1.79, 0.33)         −1.77 (−4.54, 1.00)                 ---                0.92 (0.54, 1.58)
  Ropinirole       Bromocriptine             ---                 0.06 (−0.77, 0.89)                  ---                         
  Selegiline       Bromocriptine   **−1.00 (−1.28, −0.72)**   **−3.00 (−3.34, −2.66)**    **−4.10 (−4.64, −3.56)**    **0.62 (0.39, 0.98)**
  Levodopa          Cabergoline      −1.30 (−3.32, 0.72)         −0.70 (−5.86, 4.46)                 ---                0.72 (0.47, 1.11)
  Pergolide          Levodopa         1.88 (−0.34, 4.11)        **5.10 (3.33, 6.87)**      **8.50 (5.53, 11.47)**       1.17 (0.76, 1.79)
  Pramipexole        Levodopa      **−0.88 (−1.56, −0.19)**      −1.93 (−4.82, 0.96)         −2.12 (−5.51, 1.27)      **1.43 (1.00, 2.04)**
  Ropinirole         Levodopa         0.60 (−0.20, 1.40)         1.50 (−7.85, 10.84)        **2.60 (0.03, 5.17)**       1.04 (0.72, 1.50)
  Selegiline         Levodopa      **−0.80 (−1.15, −0.45)**   **−0.40 (−0.74, −0.06)**    **−1.30 (−1.93, −0.67)**      1.96 (0.67, 5.75)
  Rasagiline        Pramipexole              ---                         ---                         ---                0.40 (0.10, 1.57)
  Ropinirole        Pramipexole       0.40 (−0.47, 1.27)         0.20 (−1.94, 2.34)                  ---                0.76 (0.42, 1.35)
  Rotigotine        Pramipexole              ---                 1.60 (−0.03, 3.23)                  ---                       ---
  Rotigotine        Ropinirole       −0.60 (−1.63, 0.43)         −1.40 (−3.21, 0.41)                 ---                1.14 (0.63, 2.09)

Abbreviation: UPDRS, Unified Parkinson's Disease Rating Scale.

###### Network meta-analysis results for UPDRS II, UPDRS III, UPDRS total represented by mean difference (MD) and 95% credible interval (CrI), withdrawals represented by odds ratio (OR) and 95% CrI. In lower half of the table, row treatments are compared against column treatments, whereas in the upper half, column treatments are compared against row treatments.

  UPDRS III                                                                                                                                                                                                                                                             
  ------------- --------------- ----------------------- ----------------------- --------------------- ---------------------- ---------------------- ----------------------- ---------------------- ---------------------- ---------------------- ---------------------- ----------------------
                    Placebo             Placebo          −3.18 (−5.91, −0.44)    −3.64 (−8.70, 1.33)    0.85 (−3.04, 4.56)    −4.33 (−6.85, −1.83)    0.11 (−5.15, 5.19)     −4.38 (−6.09, −2.67)   −2.06 (−5.06, 0.79)    −4.05 (−6.08, −2.04)   −3.09 (−5.37, −0.79)   −4.15 (−6.63, −1.70)
                 Bromocriptine    −0.74 (−2.26, 0.78)        Bromocriptine       −0.47 (−5.13, 4.17)    4.04 (−0.78, 8.66)    −1.16 (−4.35, 1.98)     3.30 (−2.39, 8.82)     −1.19 (−4.20, 1.74)     1.10 (−2.91, 5.08)    −0.87 (−3.41, 1.64)     0.13 (−3.49, 3.57)    −0.97 (−4.49, 2.54)
                  Cabergoline     −1.42 (−3.74, 0.84)     −0.66 (−2.80, 1.39)        Cabergoline       4.48 (−1.86, 10.89)    −0.67 (−5.74, 4.39)     3.72 (−3.05, 10.63)    −0.74 (−5.92, 4.45)     1.60 (−4.25, 7.40)    −0.40 (−5.42, 4.63)     0.56 (−4.88, 6.05)    −0.51 (−5.93, 5.10)
                  Lazabemide      0.80 (−0.75, 2.33)      1.55 (−0.61, 3.74)     2.22 (−0.53, 4.99)         Lazabemide        −5.20 (−9.77, −0.65)    −0.71 (−7.29, 5.70)    −5.25 (−9.38, −1.09)   −2.92 (−7.70, 1.83)    −4.93 (−9.21, −0.58)   −3.94 (−8.32, 0.47)    −5.00 (−9.53, −0.36)
                   Levodopa      −1.62 (−2.74, −0.49)     −0.87 (−2.54, 0.78)    −0.20 (−2.43, 2.03)   −2.43 (−4.33, −0.50)         Levodopa          4.45 (−0.17, 8.91)     −0.04 (−2.55, 2.41)     2.25 (−1.60, 6.14)     0.28 (−2.45, 2.96)     1.30 (−2.09, 4.57)     0.18 (−3.08, 3.53)
  UPDRS II         Pergolide      0.17 (−1.90, 2.34)      0.92 (−1.51, 3.37)     1.60 (−1.23, 4.45)    −0.62 (−3.22, 2.02)     1.79 (0.01, 3.63)           Pergolide         −4.50 (−9.56, 0.82)    −2.18 (−8.17, 3.83)    −4.19 (−9.44, 1.24)    −3.18 (−8.73, 2.49)    −4.24 (−9.81, 1.49)
                  Pramipexole    −1.60 (−2.33, −0.87)     −0.84 (−2.45, 0.71)    −0.18 (−2.46, 2.14)   −2.40 (−4.09, −0.66)    0.03 (−1.11, 1.17)     −1.77 (−3.92, 0.38)        Pramipexole         2.33 (−1.16, 5.63)     0.32 (−2.06, 2.73)     1.31 (−1.44, 4.03)     0.25 (−2.72, 3.17)
                  Rasagiline      −0.42 (−1.69, 0.88)     0.33 (−1.67, 2.28)     1.02 (−1.67, 3.63)    −1.21 (−3.23, 0.79)     1.20 (−0.50, 2.88)     −0.58 (−3.15, 1.88)     1.18 (−0.30, 2.67)         Rasagiline        −2.02 (−5.61, 1.64)    −1.04 (−4.60, 2.78)    −2.10 (−5.83, 1.80)
                  Ropinirole     −1.69 (−2.72, −0.67)     −0.93 (−2.74, 0.80)    −0.26 (−2.74, 2.19)   −2.50 (−4.34, −0.64)   −0.08 (−1.47, 1.31)     −1.87 (−4.20, 0.39)    −0.10 (−1.34, 1.10)    −1.27 (−2.95, 0.37)         Ropinirole         0.97 (−1.93, 3.90)    −0.10 (−3.19, 3.09)
                  Rotigotine     −1.40 (−2.35, −0.46)     −0.65 (−2.42, 1.12)    0.02 (−2.43, 2.50)    −2.20 (−4.01, −0.40)    0.22 (−1.24, 1.67)     −1.58 (−3.90, 0.72)     0.18 (−0.95, 1.35)    −0.98 (−2.60, 0.61)     0.29 (−1.03, 1.64)         Rotigotine        −1.06 (−4.39, 2.27)
                  Selegiline     −1.53 (−2.59, −0.43)     −0.77 (−2.50, 0.97)    −0.10 (−2.50, 2.36)   −2.32 (−4.20, −0.45)    0.11 (−1.37, 1.57)     −1.70 (−4.01, 0.60)     0.06 (−1.22, 1.38)    −1.11 (−2.76, 0.58)     0.17 (−1.28, 1.64)    −0.11 (−1.54, 1.32)         Selegiline
  Withdrawals                                                                                                                                                                                                                                                           
                   Treatment            Placebo              Bromocriptine           Cabergoline            Lazabemide              Levodopa               Pergolide             Pramipexole             Rasagiline             Ropinirole             Rotigotine             Selegiline
                    Placebo             Placebo            1.57 (0.99, 2.45)      1.06 (0.55, 2.11)     0.62 (0.21, 1.93)      0.61 (0.42, 0.92)       1.02 (0.57, 1.88)      1.10 (0.84, 1.46)      0.93 (0.68, 1.29)      0.68 (0.49, 0.97)      0.78 (0.53, 1.13)      1.49 (0.96, 2.39)
                 Bromocriptine   −0.36 (−10.69, 10.34)       Bromocriptine        0.68 (0.35, 1.32)     0.40 (0.12, 1.37)      0.39 (0.23, 0.66)       0.66 (0.32, 1.37)      0.71 (0.44, 1.15)      0.59 (0.34, 1.05)      0.44 (0.25, 0.76)      0.49 (0.28, 0.88)      0.95 (0.54, 1.72)
  UPDRS total     Cabergoline             ---                     ---                Cabergoline        0.59 (0.16, 2.18)      0.58 (0.31, 1.08)       0.97 (0.41, 2.29)      1.04 (0.52, 2.08)      0.87 (0.42, 1.83)      0.64 (0.31, 1.31)      0.73 (0.34, 1.54)      1.40 (0.65, 3.05)
                  Lazabemide      1.78 (−5.25, 8.94)     2.12 (−10.80, 14.80)            ---                Lazabemide         0.98 (0.30, 3.19)       1.63 (0.46, 5.73)      1.75 (0.56, 5.54)      1.49 (0.46, 4.78)      1.09 (0.34, 3.46)      1.23 (0.38, 3.94)      2.38 (0.72, 7.84)
                   Levodopa       −0.44 (−7.24, 6.71)    −0.11 (−10.99, 11.01)           ---           −2.30 (−11.98, 8.12)         Levodopa           1.68 (0.89, 3.15)      1.80 (1.17, 2.75)      1.51 (0.91, 2.51)      1.12 (0.70, 1.75)      1.27 (0.73, 2.14)      2.43 (1.42, 4.23)
                   Pergolide      8.19 (−5.83, 22.61)     8.40 (−7.90, 25.00)            ---           6.39 (−9.76, 22.48)    8.61 (−4.24, 21.13)          Pergolide          1.08 (0.57, 2.03)      0.91 (0.45, 1.77)      0.67 (0.34, 1.28)      0.76 (0.37, 1.51)      1.46 (0.70, 3.07)
                  Pramipexole     −1.00 (−6.66, 5.02)    −0.70 (−11.63, 10.64)           ---           −2.81 (−11.78, 6.63)   −0.54 (−6.18, 5.10)    −9.19 (−22.83, 4.50)        Pramipexole         0.84 (0.55, 1.28)      0.62 (0.40, 0.95)      0.70 (0.44, 1.09)      1.34 (0.80, 2.29)
                  Rasagiline      −2.89 (−7.66, 1.72)    −2.53 (−14.30, 8.98)            ---           −4.67 (−13.32, 3.90)   −2.41 (−11.16, 5.75)   −11.01 (−26.20, 3.79)   −1.89 (−9.74, 5.32)         Rasagiline         0.74 (0.45, 1.18)      0.83 (0.50, 1.36)      1.60 (0.93, 2.82)
                  Ropinirole     2.21 (−11.78, 16.68)    2.57 (−14.37, 19.10)            ---           0.30 (−15.37, 16.43)   2.62 (−9.84, 14.91)    −5.98 (−23.47, 11.90)   3.19 (−10.28, 16.71)   5.02 (−9.67, 20.27)         Ropinirole         1.13 (0.69, 1.82)      2.17 (1.27, 3.84)
                  Rotigotine              ---                     ---                    ---                   ---                    ---                     ---                    ---                    ---                    ---                 Rotigotine         1.93 (1.08, 3.51)
                  Selegiline     −6.04 (−11.07, −0.83)   −5.72 (−16.35, 4.83)            ---           −7.77 (−16.58, 1.09)   −5.60 (−13.67, 2.23)   −14.16 (−28.85, 0.53)   −5.05 (−12.69, 2.18)   −3.11 (−10.10, 3.83)   −8.24 (−23.07, 6.30)           ---                 Selegiline

Abbreviation: UPDRS, Unified Parkinson's Disease Rating Scale.

###### Surface under the cumulative ranking curve (SUCRA) results.

                   UPDRS II    UPDRS III   UPDRS total   Withdrawals
  --------------- ----------- ----------- ------------- -------------
  Placebo            0.214       0.138        0.443         0.445
  Bromocriptine      0.440       0.536        0.510         0.093
  Cabergoline        0.661       0.613         ---          0.403
  Lazabemide         0.082       0.097        0.336       **0.762**
  Levodopa         **0.749**   **0.761**      0.508       **0.877**
  Pergolide          0.205       0.189        0.121         0.427
  Pramipexole      **0.738**   **0.777**    **0.565**       0.325
  Rasagiline         0.259       0.395      **0.721**       0.531
  Ropinirole       **0.773**     0.710        0.369       **0.807**
  Rotigotine         0.649       0.536         ---          0.704
  Selegiline         0.708       0.716        0.918         0.117
